S&P 500   3,935.87 (-1.57%)
DOW   33,546.89 (-1.18%)
QQQ   282.18 (-1.90%)
AAPL   143.97 (-1.81%)
MSFT   245.30 (-1.96%)
META   114.65 (-6.35%)
GOOGL   97.48 (-2.01%)
AMZN   88.82 (-2.41%)
TSLA   178.24 (-2.31%)
NVDA   160.43 (-3.41%)
NIO   13.04 (+1.88%)
BABA   91.38 (+0.95%)
AMD   70.80 (-3.83%)
T   19.00 (+1.33%)
MU   53.67 (-0.68%)
CGC   3.61 (-16.44%)
F   13.10 (-2.09%)
GE   84.99 (+0.39%)
DIS   93.09 (-2.96%)
AMC   6.73 (-9.66%)
PYPL   72.14 (-2.01%)
PFE   49.42 (-2.58%)
NFLX   306.29 (-2.02%)
S&P 500   3,935.87 (-1.57%)
DOW   33,546.89 (-1.18%)
QQQ   282.18 (-1.90%)
AAPL   143.97 (-1.81%)
MSFT   245.30 (-1.96%)
META   114.65 (-6.35%)
GOOGL   97.48 (-2.01%)
AMZN   88.82 (-2.41%)
TSLA   178.24 (-2.31%)
NVDA   160.43 (-3.41%)
NIO   13.04 (+1.88%)
BABA   91.38 (+0.95%)
AMD   70.80 (-3.83%)
T   19.00 (+1.33%)
MU   53.67 (-0.68%)
CGC   3.61 (-16.44%)
F   13.10 (-2.09%)
GE   84.99 (+0.39%)
DIS   93.09 (-2.96%)
AMC   6.73 (-9.66%)
PYPL   72.14 (-2.01%)
PFE   49.42 (-2.58%)
NFLX   306.29 (-2.02%)
S&P 500   3,935.87 (-1.57%)
DOW   33,546.89 (-1.18%)
QQQ   282.18 (-1.90%)
AAPL   143.97 (-1.81%)
MSFT   245.30 (-1.96%)
META   114.65 (-6.35%)
GOOGL   97.48 (-2.01%)
AMZN   88.82 (-2.41%)
TSLA   178.24 (-2.31%)
NVDA   160.43 (-3.41%)
NIO   13.04 (+1.88%)
BABA   91.38 (+0.95%)
AMD   70.80 (-3.83%)
T   19.00 (+1.33%)
MU   53.67 (-0.68%)
CGC   3.61 (-16.44%)
F   13.10 (-2.09%)
GE   84.99 (+0.39%)
DIS   93.09 (-2.96%)
AMC   6.73 (-9.66%)
PYPL   72.14 (-2.01%)
PFE   49.42 (-2.58%)
NFLX   306.29 (-2.02%)
S&P 500   3,935.87 (-1.57%)
DOW   33,546.89 (-1.18%)
QQQ   282.18 (-1.90%)
AAPL   143.97 (-1.81%)
MSFT   245.30 (-1.96%)
META   114.65 (-6.35%)
GOOGL   97.48 (-2.01%)
AMZN   88.82 (-2.41%)
TSLA   178.24 (-2.31%)
NVDA   160.43 (-3.41%)
NIO   13.04 (+1.88%)
BABA   91.38 (+0.95%)
AMD   70.80 (-3.83%)
T   19.00 (+1.33%)
MU   53.67 (-0.68%)
CGC   3.61 (-16.44%)
F   13.10 (-2.09%)
GE   84.99 (+0.39%)
DIS   93.09 (-2.96%)
AMC   6.73 (-9.66%)
PYPL   72.14 (-2.01%)
PFE   49.42 (-2.58%)
NFLX   306.29 (-2.02%)
Top-Rated Stocks  
NASDAQ:STAA

STAAR Surgical - STAA Stock Forecast, Price & News

$60.52
-1.81 (-2.90%)
(As of 12/6/2022 01:04 PM ET)
Add
Compare
Today's Range
$59.97
▼
$61.72
50-Day Range
$55.30
▼
$76.20
52-Week Range
$49.03
▼
$112.27
Volume
5,496 shs
Average Volume
561,337 shs
Market Capitalization
$2.92 billion
P/E Ratio
79.63
Dividend Yield
N/A
Price Target
$92.89

STAAR Surgical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
54.4% Upside
$92.89 Price Target
Short Interest
Healthy
4.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.24mentions of STAAR Surgical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.66 M Sold Last Quarter
Proj. Earnings Growth
44.00%
From $0.75 to $1.08 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.27 out of 5 stars

Medical Sector

1st out of 1,023 stocks

Ophthalmic Goods Industry

1st out of 7 stocks

See Top Rated MarketRank™ Stocks Here
STAA stock logo

About STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Stock News Headlines

December 2, 2022 | americanbankingnews.com
Short Interest in STAAR Surgical (NASDAQ:STAA) Drops By 22.8%
December 2, 2022 | americanbankingnews.com
STAAR Surgical (NASDAQ:STAA) Price Target Cut to $79.00
November 28, 2022 | finance.yahoo.com
Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)
November 28, 2022 | americanbankingnews.com
STAAR Surgical (NASDAQ:STAA) Receives $94.89 Average PT from Analysts
November 28, 2022 | americanbankingnews.com
Brokerages Set STAAR Surgical (NASDAQ:STAA) Target Price at $94.89
November 17, 2022 | finance.yahoo.com
STAAR Surgical Opens EVO Experience Center in United States
November 13, 2022 | finance.yahoo.com
Is Now An Opportune Moment To Examine STAAR Surgical Company (NASDAQ:STAA)?
November 11, 2022 | finance.yahoo.com
Are Options Traders Betting on a Big Move in STAAR (STAA) Stock?
November 3, 2022 | markets.businessinsider.com
What 8 Analyst Ratings Have To Say About Staar Surgical
November 3, 2022 | seekingalpha.com
STAAR Surgical Company (STAA) Q3 2022 Earnings Call Transcript
November 2, 2022 | finance.yahoo.com
Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates
November 2, 2022 | markets.businessinsider.com
STAAR Surgical Company Q3 Profit Increases, beats estimates
November 2, 2022 | finance.yahoo.com
STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y
October 29, 2022 | finance.yahoo.com
STAAR Surgical's (NASDAQ:STAA) investors will be pleased with their enviable 465% return over the last five years
October 20, 2022 | nz.finance.yahoo.com
$13+ Billion Contact Lenses Market Size to Grow at a CAGR of 5.1% by 2028 | The Insight Partners
October 19, 2022 | finance.yahoo.com
STAAR Surgical to Report Third Quarter Results on November 2, 2022
October 14, 2022 | markets.businessinsider.com
Tesla To $230? Plus Canaccord Genuity Cuts PT On T2 Biosystems By 80%
October 14, 2022 | nasdaq.com
Here's Why We Think STAAR Surgical (NASDAQ:STAA) Is Well Worth Watching
October 13, 2022 | markets.businessinsider.com
Expert Ratings for Staar Surgical
October 12, 2022 | finance.yahoo.com
Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses
October 7, 2022 | finance.yahoo.com
Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"
October 2, 2022 | finance.yahoo.com
2 Evergreen Growth Stocks to Buy and Hold Forever
October 2, 2022 | fool.com
STAAR Surgical (NASDAQ: STAA)
September 29, 2022 | marketwatch.com
Ophthalmology Devices Market : Research Report Analysis by Competitors, Sales, Revenue and Industry Size 2022 To 2027
September 29, 2022 | marketwatch.com
Ophthalmology Devices Market 2022 Industry Outlook, Current Status, Supply-Demand, Growth Opportunities and Top Players Analysis 2027
See More Headlines
Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Company Calendar

Last Earnings
11/02/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Ophthalmic goods
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:STAA
CUSIP
85231230
CIK
718937
Web
www.staar.com
Phone
(626) 303-7902
Fax
626-303-2962
Employees
692
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$92.89
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$79.00
Forecasted Upside/Downside
+53.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.76
Trailing P/E Ratio
79.63
Forward P/E Ratio
80.69
P/E Growth
N/A
Net Income
$24.50 million
Net Margins
13.54%
Pretax Margin
16.66%
Return on Equity
15.13%
Return on Assets
11.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.55
Quick Ratio
6.11

Sales & Book Value

Annual Sales
$230.47 million
Price / Sales
12.66
Cash Flow
$0.64 per share
Price / Cash Flow
94.33
Book Value
$5.43 per share
Price / Book
11.15

Miscellaneous

Outstanding Shares
48,210,000
Free Float
46,953,000
Market Cap
$2.92 billion
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Ms. Caren L. MasonMs. Caren L. Mason (Age 68)
    CEO, Pres & Director
    Comp: $1.97M
  • Mr. Patrick F. WilliamsMr. Patrick F. Williams (Age 49)
    Chief Financial Officer
    Comp: $934.82k
  • Dr. Keith HollidayDr. Keith Holliday (Age 59)
    Chief Technology Officer
    Comp: $822.97k
  • Mr. Hans-Martin Blickensdoerfer (Age 57)
    Consultant
    Comp: $756.58k
  • Dr. Scott D. Barnes M.D. (Age 59)
    Chief Medical Officer
    Comp: $874.46k
  • Mr. Brian Moore
    VP of Investor, Media Relations & Corp. Devel.
  • Mr. Samuel J. GestenMr. Samuel J. Gesten (Age 60)
    Chief Legal Officer & Corp. Sec.
  • Mr. James Francese (Age 58)
    Sr. VP of Commercial Operations - North America & APAC
  • Joanne Egamino Ph.D.
    Global Head of Clinical Operations
  • Mr. Philippe Subrin (Age 58)
    VP of Collamer Lens Manufacturing & GM of Nidau Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













STAA Stock - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.

What is STAAR Surgical's stock price forecast for 2023?

9 brokers have issued twelve-month target prices for STAAR Surgical's shares. Their STAA share price forecasts range from $79.00 to $125.00. On average, they anticipate the company's stock price to reach $92.89 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.

How have STAA shares performed in 2022?

STAAR Surgical's stock was trading at $91.30 at the start of the year. Since then, STAA shares have decreased by 33.5% and is now trading at $60.72.
View the best growth stocks for 2022 here.

Are investors shorting STAAR Surgical?

STAAR Surgical saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 2,370,000 shares, a drop of 22.8% from the October 31st total of 3,070,000 shares. Based on an average trading volume of 458,300 shares, the days-to-cover ratio is currently 5.2 days.
View STAAR Surgical's Short Interest.

When is STAAR Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our STAA earnings forecast.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) issued its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.12. The medical instruments supplier had revenue of $76.05 million for the quarter, compared to the consensus estimate of $74.95 million. STAAR Surgical had a trailing twelve-month return on equity of 15.13% and a net margin of 13.54%. STAAR Surgical's revenue was up 30.3% on a year-over-year basis. During the same quarter last year, the business posted $0.13 earnings per share.

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285.00 million-$285.00 million, compared to the consensus revenue estimate of $294.94 million.

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.61%), Vanguard Group Inc. (10.83%), Baillie Gifford & Co. (10.67%), State Street Corp (3.25%), Palo Alto Investors LP (2.28%) and Geneva Capital Management LLC (1.97%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends.

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $60.72.

How much money does STAAR Surgical make?

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $2.93 billion and generates $230.47 million in revenue each year. The medical instruments supplier earns $24.50 million in net income (profit) each year or $0.76 on an earnings per share basis.

How many employees does STAAR Surgical have?

The company employs 692 workers across the globe.

Does STAAR Surgical have any subsidiaries?
The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More
How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.

This page (NASDAQ:STAA) was last updated on 12/6/2022 by MarketBeat.com Staff